Page 8 - Nsclc News Today

Benjamin Levy, MD, discusses the role of molecular testing in patients with advanced NSCLC.

Patients with advanced NSCLC who received optimal first-line treatment based on biomarker testing demonstrated better outcomes, new findings showed.

Patients with metastatic cancer are increasingly starting immunotherapy within a month prior to death, new data show.

Radiation dose-escalation combined with stereotactic ablative radiotherapy may improve locoregional control in patients with NSCLC.

Click here to read this study in JAMA Network Open. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine,

Jason Porter, MD, highlights the implications of recent data to emerge following the use of EGFR TKIs in the adjuvant setting, the importance of the potential upcoming FDA approval of osimertinib with chemotherapy in EGFR-positive non–small cell lung cancer, and more.

Molly Mendenhall, BSN, RN, director of quality and compliance at Oncology Hematology Care, Inc (OHC), discussed a 1-year quality improvement project implemented by OHC to standardize comprehensive biomarker testing in patients with non–small cell lung cancer (NSCLC).

A PMA application seeking approval of TTFields to standard therapies in patients with non­–small cell lung cancer has been accepted for filing by the FDA.

The initiation of immunotherapy at the end of life among patients with advanced cancers is increasing over time.

The European Commission has granted marketing authorization for subcutaneous atezolizumab co-formulated with Enhanze, a recombinant human hyaluronidase enzyme rHuPH20, for all approved indications of intravenous atezolizumab.